Secondary Logo

Journal Logo



JAIDS Journal of Acquired Immune Deficiency Syndromes: April 2019 - Volume 81 - Issue - p 3-12
doi: 10.1097/01.qai.0000557938.04216.a6
  • Free

20th Annual International Meeting of the Institute of Human Virology at the University of Maryland School of Medicine

Dear Colleagues and Friends,

You are invited to join us on Monday, October 22 through Thursday, October 25 for IHV2018, “Virus Threats and Cancers–A Special Joint International Meeting of the Institute of Human Virology and the Global Virus Network.” Sessions for this year’s meeting will focus on: The 40th Anniversary of the Discovery of the First Human Retrovirus, HTLV, Exosomes in Health and Disease, Cancer Immunology, Cancer Epigenetics, Cancer Microenvironments, Viruses, the Emerging Global Health Challenge, PEPFAR: Towards HIV Epidemic Control, Targeting Early Infections, Approaches to Eliminate Persistent Viruses, Early stage investigators are invited to submit research abstracts for poster presentation—please share this opportunity with your faculty and colleagues.

A special mini-symposium, “The 15th Anniversary of PEPFAR” will honor PEPFAR as the largest public health program in global history, and its sustainable impact on global health priorities. This year's meeting will honor IHV Lifetime Achievement Awardees: Lifetime Achievement Award for Excellence in Medical Education, Clinical Care and Clinical Research: Henry Masur, MD, Chief of Critical Care Medicine Department, NIH Clinical Center and the Lifetime Achievement Award for Excellence in Clinical Research: Kiyoshi Takatsuki, MD, PhD, Professor Emeritus, Kumamoto University.

The Annual Awards Gala will be held Wednesday, October 24 at the Four Seasons Hotel, Baltimore. A gala reception will begin at 6:30 pm followed by dinner at 7:15 pm. We look forward to welcoming you to Baltimore this October as we continue our annual tradition of excellent science and provocative discussion.


Robert C. Gallo, MD

Homer and Martha Gudelsky

Distinguished Professor in Medicine

Director, Institute of Human Virology

Co-Founder and Director, Global Virus Network

Manhattan Charurat, PhD

Director, Division of Epidemiology and Prevention

Professor of Medicine, Institute of Human Virology

Mission Statement

The Institute was established to create and develop a world-class center of excellence focusing on chronic viral diseases, especially HIV/AIDS, and virally-linked cancers.

The IHV is dedicated to the discovery, research, treatment and prevention of these disease.

Its unique structure seeks to connect cohesive, multi-disciplinary research and clinical programs so that new treatments are streamlined from discovery to patient. The IHV serves patients locally and the scientific community globally.

Robert Gallo, MD


Man Charurat, PhD


Division of Epidemiology and Prevention

Shyam Kottilil, MBBS, PhD


Division of Clinical Care & Research

George Lewis, PhD


Division of Vaccine Research

Yang Liu, PhD


Division of Immunotherapy

Wuyuan Lu, PhD


Division of Basic Science

Eric Sundberg, PhD


Division of Basic Science

Anthony Amoroso, MD

Associate Director

Division of Clinical Care & Research

Deus Bazira, DrPH, MPH, MBA


Center for International Health, Education & Biosecurity (CIHEB)

Dave Wilkins

Chief Operating Officer

Institute of Human Virology (IHV) Board of Advisors

Terry Lierman, Co-Chair

Summit Global Ventures

John Evans, Co-Chair

Evans Telecommunications

Peter Angelos, Esquire

The Law Offices of Peter Angelos

Joseph Berardino

Alvarez & Marsal

William A. Blattner, MD

Institute of Human Virology, Retired

Christian Bréchot, MD, PhD

Global Virus Network (GVN)

Robert L. Caret, PhD

University System of Maryland

Barbara Culliton

Science Journalist and Policy Consultant

The Honorable Elijah Cummings

US House of Representatives

The Honorable Arthur J. Gajarsa


Michael Greenebaum

Greenebaum Enterprises

Sheilah A. Kast

On the Record, WYPR

Mark H. Kapan, MD, FACP

University of Michigan Health System

John R. Kelly

Kelly & Associates Insurance Group (KELLY)

KELLY Benefit Strategies & KELLY Advisory

William E. Kirwan, PhD

University System of Maryland

The Honorable Nancy Kopp

Maryland State Treasurer

Anna B. Laakmann, Esquire

Greenberg Traurig LLP

Thomas G. Lynch

Ireland East Hospital Group

John McHutchison, MD

Gilead Sciences, Inc.

Charles Modica, JD

St. George’s University

Timothy Moynahan, Esquire

The Moynahan Law Firm, LLC

Franco Nuschese

Georgetown Entertainment Group

Joseph S. Pagano, MD

University of North Carolina at Chapel Hill

Peter Palese, PhD

Mount Sinai School of Medicine

James P. Pinkerton

RATE Coalition

The Honorable Catherine E. Pugh

Mayor of Baltimore

Ellen Ratner

Talk Radio News Service

Guangqi Tian

Sino Invest Limited

The Honorable Kathleen Kennedy Townsend

The Rock Creek Group

Jeff B. Trammell

Trammell and Company

Lenny Wilkens

NBA Hall of Fame Coach and Player

Danny Wong


Ambassador R. James Woolsey

Lux Capital Management

Steven Wozencraft

John D. Evans Foundation

The Honorable Ernest F. Hollings, Honorary

Princess Chulabhorn Mahidol, Honorary

IHV Scientific Advisory Board

Joseph Pagano, MD, Chair

University of North Carolina

Edward Berger, PhD


Carlo M. Croce, MD

The Ohio State University

William DeGrado, PhD

University of California, San Francisco

Max Essex, DVM, PhD

Harvard AIDS Institute

Warner C. Greene, MD, PhD

Gladstone Institute of Virology and Immunology

Diane E. Griffin, MD, PhD

Johns Hopkins Bloomberg School of Public Health

Mark H. Kaplan, MD

University of Michigan Health System

Michel Klein, MD

VaxiBio, Inc.

John W. Mellors, MD

University of Pittsburgh

Douglas Nixon, MD, PhD

The George Washington University

Erling C. J. Norrby, MD, PhD

The Royal Swedish Academy of Sciences

Peter Palese, PhD

Mount Sinai School of Medicine

Jeffrey V. Ravetch, MD, PhD

Rockefeller University

Michael Saag, MD

University of Alabama at Birmingham

Center for AIDS Research

Erica Ollmann Saphire, PhD

The Scripps Research Institute

Mario Stevenson, PhD

University of Miami

David Thomas, MD, MPH

Johns Hopkins Medicine

Sten H. Vermund, MD, PhD

Yale School of Public Health

Organizing Committees

The Institute of Human Virology at the University of Maryland School of Medicine is grateful for the assistance provided by our International and Local Organizing Committees.

International Organizing Committee

Robert C. Gallo, MD

Director, Institute of Human Virology

Roberto Accolla, MD, PhD

University of Insubria

Quarraisha Abdool Salim, PhD


Alash'le Abimiku, MON, PhD

Institute of Human Virology

Local Organizing Committee

Anthony DeVico, PhD

Institute of Human Virology

Eric Sundberg, PhD

Institute of Human Virology

Yang Lui, PhD

Institute of Human Virology

Deus Mubangizi, DrPH, MPH

Institute of Human Virology

Clement Adebamowo, BM, ChB Hons, FWACS, ScD

Institute of Human Virology

George Lewis, PhD

Institute of Human Virology

Nadia Sam-Agudu, MD

Institute of Human Virology

Shyamasundaran Kottilil, MD, PhD

Institute of Human Virology

Yutaka Tagaya, MD, PhD

Institute of Human Virology

Communications and Press Policy

To enhance the exchange of information and communication among attendees of IHV2018, the following must be adhered to by all participants:

• All comments at sessions are off-the-record and not for attribution.

• To No coverage, reporting or publication of scientific data or presentations at IHV2018 is permitted without the written consent of the presenter(s) and Nora Samaranayake (info below). This rule applies to all forms of media, including blogging, tweeting, etc.

• Alternatively, if content comprises public comments made during the closed meeting, media are acceptable without written consent. If you are not sure if the comments can be publicized, please err on the side of caution and contact Nora Samaranayake.

One-on-one interviews with scientists and media may be arranged by contacting Nora Samaranayake, Director of Public Relations and Marketing, Institute of Human Virology, (410) 706-8614 or [email protected]

Those registering for the meeting as “press” must provide their credentials within 3 days of registration to Amina Teal, [email protected]

Special Acknowledgements

The Institute of Human Virology wishes to recognize, with gratitude, the following sponsors.

*Funding for this conference was made possible in part by 2 R13 AI 046078—19 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

The 2018 IHV Lifetime Achievement Award for Excellence in Medical Education, Clinical Care and Clinical Research

Hnry Masur, MD

Henry Masur, MD is the Chief of Critical Care Medicine Department at the NIH Clinical Center. He trained in infectious diseases at Cornell-New York Hospital. In the early 1980's he recognized some of the first patients with HIV infection, and initiated a program in New York that described the emerging manifestation of AIDS. In 1982 he was recruited to join the Critical Care Medicine Department at the NIH-Clinical Center. He built a multidisciplinary group that focused on understanding the pathogenesis and natural history of HIV-related opportunistic infections including pneumocystis, CMV, Mycobacterium avium complex, and Cryptococcus. His team did initial studies on new diagnostics and new therapeutic agents for these organisms that form the basis of diagnostic, therapeutic, and preventive management strategies that are still in use.

At NIH, his group was able to determine that pneumocystis was a fungus rather than a protozoa, they were able to develop the diagnostic immunofluorescent test still in use in most laboratories, they did early work on PCR diagnostics, and they sequenced the human, mouse and rate pneumocystis in order to understand the unique characteristics of this organism and how to develop new therapeutic and preventive strategies.

Recognizing that practicing physicians had a difficult time keeping up with new developments in this rapidly emerging field, Dr. Masur initiated the first NIH sponsored guideline related to AIDS management, with a focus on opportunistic infections. This guideline became a model for subsequent NIH or HHS sponsored guidelines on antiretroviral therapy, and pediatric and neonatal management. Each year there are over 1.5 million page views of these documents which serve as a global gold standard for clinical care.

Dr. Masur has been active in other fields including the management of infections in the ICU. He was Chair of the FDA Advisory Panel on Antiviral Drugs for over 10 years. He has been President, Infectious Disease Society of America.

In 2006 he worked with Anthony Fauci and Carl Dieffenbach of NIAID, and Alan Greenberg of the George Washington University School of Public Health and Health Policy, to develop a unique partnership, the DC Partnership for AIDS Progress, between NIH and the District of Columbia Department of Public Health to create a model in the District of Columbia on how urban areas in the US could more effectively deal with the HIV epidemic. That program now includes the nation's largest urban HIV cohort, with almost 10,000 patients, and a clinical program focusing on HIV comorbidities and implementation strategies to increase ART and PREP adherence. In a cooperative agreement with the University of Maryland and IHV, this partnership has been a national leader in developing directly acting agents for HCV. Dr Masur serves as Co-Chair of the first IDSA-AASLD guidelines committee for management of HCV.

The 2018 IHV Lifetime Achievement Award for Excellence in Clinical Research

Kiyoshi Takatsuki, MD, PhD

Kiyoshi Takatsuki, MD, PhD, Professor Emeritus of the Kumamoto University, is a hematologist whose research primarily focused on Adult T-cell leukemia (ATL), a T-cell malignancy caused by Human T-cell Leukemia Virus (HTLV)-1. Dr. Takatsuki graduated from the Kyoto University Medical School, and studied multiple myeloma there in the days when the word “Immunoglobulin” was not yet in use. Around 1973, Dr. Takatsuki and co-workers noticed a peculiar type of leukemia which was seen with patients from South-Western part (Kyushu and Okinawa) of Japan. The leukemic cells from these patients show special indentation or lobulation of cellular nuclei. Dr. Takatsuki’s group later proved that that these leukemic cells are of T-cell origin. In 1977, Dr. Takatsuki and co-workers made a seminal report that this is a new clinical disease and named it as ATL.

The discovery of ATL by Dr. Takatsuki’s group had rippling effects on numerous fields of medical biology, oncology, virology and unexpectedly, neurology as HTLV-1 was later shown to cause HAM/TSP (HTLV-1 associated myelopathy/Tropical spastic paraparesis), a progressive and paralytic neurological disorder. Above all, it led to the discovery of the first human oncogenic retrovirus by Dr. Robert Gallo's group at the NCI in 1980. Independently, a Japanese group led by Dr. Yorio Hinuma identified a new type C retrovirus (1981) from an ATL cell line. Subsequent studies confirmed that these two viruses were identical, which is now known as the Human T-cell leukemia Virus-1 (HTLV-1).

Dr. Takatsuki's group continued extensive clinical and basic research on ATL and HTLV-1. They defined the clinical classification of ATL, elucidated mechanism of oncogenesis, and developed new diagnostic methodology and new treatments. In particular, Takatsuki and his colleagues studied nearly 200 ATL patients in Kyushu, Japan (median age 55) and established the clinical features associated with this disease; lymph node enlargement, hepatomegaly, splenomegaly, and skin lesions. Skin lesions including papules, erythema, and nodules are often associated with ATL patients as ATL cells densely infiltrate the dermis and epidermis to form Pautrier's microabscesses. In addition, they found the association of hypercalcemia with 72% of ATL patients. They also discovered the familial occurrence of ATL (which prompted virologists to search for the causing virus). Later, Dr. Takatsuki and others elucidated the three routes of HTLV-1 transmission all of which require the passage of virus-infected cells. One major mode of transmission is from mothers to newborns through breast feeding. In addition, the research by Takatsuki and others reported the sexual transmission of HTLV-1 predominantly from males to females, and transmission through blood transfusion.

Dr. Takatsuki has also mentored many young medical researchers who have now become leaders of the HTLV-1/ATL research field.

Dr. Takatsuki has authored and co-authored more than 420 publications. Because of these outstanding scientific accomplishments, Dr. Takatsuki received numerous prestigious awards including the Princess Takamatsu Cancer Foundation Prize (1984, Tokyo), Hammer Prize (1985, Los Angeles), and the Person of Cultural Merit by the Japanese Government (1995).

Previous Recipients of IHV Lifetime Achievement Awards

Lifetime Achievement Awards for Scientific Contributions

1999 George Klein, MD, Karolinska Institute, Stockholm, Sweden

2000 Maurice Hilleman, PhD, Merck Research Laboratories, Sumneytown, Pennsylvania

2001 Hilary Koprowski, MD, Thomas Jefferson University, Philadelphia, Pennsylvania

2002 Alexander Rich, MD, Massachusetts Institute of Technology, Cambridge, Massachusetts

2003 Jan Svoboda, PhD, DSc, Institute of Molecular Genetics, Prague, Czech Republic

2004 Paul Zamecnik, MD, Massachusetts General Hospital, Boston, Massachusetts

2005 Manfred Eigen, PhD, Max Planck Institute, Gottingen, Germany

2006 Maxine Singer, PhD, National Institutes of Health, Bethesda, Maryland

2008 Isaac P. Witz, PhD, Tel Aviv University, Tel Aviv, Israel

2010 Rino Rappuoli, PhD, Novartis Vaccines, Sienna, Italy

2011 Max Essex, DVM, PhD, Harvard AIDS Institute, Boston, Massachusetts

2012 Thomas A. Waldmann, MD, National Cancer Institute, Bethesda, Maryland

2013 Vadim I. Agol, MD, PhD, DSc, Russian Academy of Medical Sciences, Moscow, Russia

2014 William Paul, MD, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

2015 Harald zur Hausen, MD, Nobel Laureate, Gelsenkirchen, Germany

2016 Peter Vogt, PhD, Scripps Research Institute, La Jolla, California

2017 Peter Palese, PhD, Icahn School of Medicine at Mount Sinai, New York, New York

Lifetime Achievement Award for Public Service

2004 Stewart Greenebaum, Greenebaum and Rose Associates, Inc., Baltimore, Maryland

2006 Martin Delaney, Project Inform, San Francisco, California

2008 John D. Evans, Evans Telecommunication Company, Miami, Florida, The Honorable Robert K. Gray, Gray and Company II, Miami, Florida

2010 Harry Huge, Esq., The Harry and Reba Huge Foundation, Charleston, South Carolina

2011 Bernadine Healy, MD, In Memoriam, Former Director, National Institutes of Health, Bethesda, MD

2012 Yi Zeng, PhD, China Centers for Disease Control, Beijing, China

2013 Jose G. Esparza, MD, PhD, Bill & Melinda Gates Foundation, Seattle, Washington

2014 John Martin, PhD, Gilead Sciences, Inc., Foster City, California

2015 Anthony S. Fauci, MD, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

2016 Raymond Schinazi, PhD, Hon DSc, Emory University, Atlanta, Georgia

2017 Quarraisha Abdool Karim, PhD, Center for the AIDS Programme of Research in South Africa, Durban, South Africa

2017 Salim Abdool Karim, MBChB, PhD, DSc, Center for the AIDS Programme of Research in South Africa, Durban, South Africa

One-Time Lifetime Achievement Award for Excellence in Teaching

2010 Michele LaPlaca, MD, Institute of Microbiology of the University of Bologna, Bologna, Italy

Lifetime Achievement Award for Excellence in Medical Education, Clinical Care and Clinical Research

2012 John G. Bartlett, MD, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.